Insights

Gathering insights about Nkarta, Inc.…

Similar companies to Nkarta, Inc.

Nkarta, Inc. Tech Stack

Nkarta, Inc. uses 8 technology products and services including Google Analytics, NetSuite, jQuery, and more. Explore Nkarta, Inc.'s tech stack below.

Google Analytics
Analytics
NetSuite
E-commerce
jQuery
Javascript Libraries
Modernizr
Javascript Libraries
Module Federation
Miscellaneous
Microsoft
Miscellaneous
Bootstrap
UI Frameworks
Apache HTTP Server
Web Servers

Media & News

Nkartatx is developing NK cell therapies for cancer treatment and autoimmune diseases.
Nkarta, headquartered in South San Francisco, California, focuses on developing allogeneic NK cell therapies for cancer treatment and autoimmune diseases.
Sep 30, 2024 | in.investing.com
Nkartatx has issues with potential of its NK cell therapy beyond cancer.
With this trial, Nkarta is expanding the therapeutic potential of its NK cell therapy beyond cancer.
Jul 24, 2024 | www.stocktitan.net
Nkartatx hired Nadir Mahmood as President on Jul 16th '24.
Nkarta announces leadership updates, appoints Nadir Mahmood as President.
Jul 16, 2024 | finance.yahoo.com
Nkartatx had issues with possible breaches of fiduciary duty on Jan 19th '24.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP notifies shareholders of an investigation concerning possible breaches of fiduciary duty by certain officers and directors of Nkarta Inc. (NASDAQ: NKTX).
Jan 18, 2024 | pr.ashlandtownnews.com
Nkartatx is developing pipeline of future cell therapies engineered for deep therapeutic activity.
By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting.
Dec 08, 2023 | stockhouse.com
Nkartatx decreases headcount by 18.
Cell therapy company Nkarta is laying off 18 people, about 10% of its staff, it revealed in an SEC filing.
Oct 18, 2023 | www.olooptech.com
Lupus Therapeutics partners with Nkartatx.
NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq: NKTX ), a biopharmaceutical company developing the engineered natural killer (NK) cell therapy NKX019 for refractory lupus nephritis that has not responded to standard treatment.
Oct 16, 2023 | www.prnewswire.com

Nkarta, Inc.'s Email Address Formats

Nkarta, Inc. uses at least 1 format(s):

Nkarta, Inc. Email Formats	Example	Percentage
FLast@nkartatx.com	JDoe@nkartatx.com	98%
Last@nkartatx.com	Doe@nkartatx.com	1%
First.Last@nkartatx.com	John.Doe@nkartatx.com	1%

Frequently Asked Questions

Where is Nkarta, Inc.'s headquarters located?

Nkarta, Inc.'s main headquarters is located at 1150 Veterans Blvd. South San Francisco, California 94080 US. The company has employees across 4 continents, including North AmericaAsiaEurope.

What is Nkarta, Inc.'s phone number?

You can contact Nkarta, Inc.'s main corporate office by phone at

+1-415-582-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Nkarta, Inc.'s stock symbol?

Nkarta, Inc. is a publicly traded company; the company's stock symbol is NKTX.

What is Nkarta, Inc.'s official website and social media links?

Nkarta, Inc.'s official website is nkartatx.com and has social profiles on LinkedIn.

How much revenue does Nkarta, Inc. generate?

As of November 2024, Nkarta, Inc.'s annual revenue reached $15M.

What is Nkarta, Inc.'s SIC code NAICS code?

Nkarta, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Nkarta, Inc. have currently?

As of November 2024, Nkarta, Inc. has approximately 167 employees across 4 continents, including North AmericaAsiaEurope. Key team members include Chief Financial And Business Officer: A. L.Chief Scientific Officer: J. T.Chief Legal Officer & Corporate Secretary: A. H.. Explore Nkarta, Inc.'s employee directory with LeadIQ.

What industry does Nkarta, Inc. belong to?

Nkarta, Inc. operates in the Biotechnology Research industry.

What technology does Nkarta, Inc. use?

Nkarta, Inc.'s tech stack includes Google AnalyticsNetSuitejQueryModernizrModule FederationMicrosoftBootstrapApache HTTP Server.

What is Nkarta, Inc.'s email format?

Nkarta, Inc.'s email format typically follows the pattern of . Find more Nkarta, Inc. email formats with LeadIQ.

How much funding has Nkarta, Inc. raised to date?

As of November 2024, Nkarta, Inc. has raised $114M in funding. The last funding round occurred on Sep 04, 2019 for $114M.

When was Nkarta, Inc. founded?

Nkarta, Inc. was founded in 2015.

Nkarta, Inc.

Biotechnology ResearchCalifornia, United States51-200 Employees

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, and engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at www.nkartatx.com.

Company Overview

Headquarters: 1150 Veterans Blvd. South San Francisco, California 94080 US
Phone number: +1-415-582-****
Website: nkartatx.com
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: NKTX
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2015
Employees: 51-200

Media & News

Funding & Financials

$114M
Nkarta, Inc. has raised a total of $114M of funding over 1 rounds. Their latest funding round was raised on Sep 04, 2019 in the amount of $114Mas a Series B.
$10M$50M
Nkarta, Inc.'s revenue is in the range of $10M$50M

Funding & Financials

$114M
Nkarta, Inc. has raised a total of $114M of funding over 1 rounds. Their latest funding round was raised on Sep 04, 2019 in the amount of $114Mas a Series B.
$10M$50M
Nkarta, Inc.'s revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Nkarta, Inc.

Rubius Therapeutics

Caribou Biosciences

Allogene Therapeutics

Editas Medicine

Tessera Therapeutics

Beam Therapeutics

LogicBio Therapeutics

CRISPR Therapeutics

Nkarta, Inc. Tech Stack

Media & News

Nkartatx is developing NK cell therapies for cancer treatment and autoimmune diseases.

Nkartatx has issues with potential of its NK cell therapy beyond cancer.

Nkartatx hired Nadir Mahmood as President on Jul 16th '24.

Nkartatx had issues with possible breaches of fiduciary duty on Jan 19th '24.

Nkartatx is developing pipeline of future cell therapies engineered for deep therapeutic activity.

Nkartatx decreases headcount by 18.

Lupus Therapeutics partners with Nkartatx.

Nkarta, Inc.'s Email Address Formats

Frequently Asked Questions

Where is Nkarta, Inc.'s headquarters located?

What is Nkarta, Inc.'s phone number?

What is Nkarta, Inc.'s stock symbol?

What is Nkarta, Inc.'s official website and social media links?

How much revenue does Nkarta, Inc. generate?

What is Nkarta, Inc.'s SIC code NAICS code?

How many employees does Nkarta, Inc. have currently?

What industry does Nkarta, Inc. belong to?

What technology does Nkarta, Inc. use?

What is Nkarta, Inc.'s email format?

How much funding has Nkarta, Inc. raised to date?

When was Nkarta, Inc. founded?

Nkarta, Inc.

Company Overview

Media & News

Nkartatx is developing NK cell therapies for cancer treatment and autoimmune diseases.

Nkartatx has issues with potential of its NK cell therapy beyond cancer.

Nkartatx hired Nadir Mahmood as President on Jul 16th '24.

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?